ProQR Therapeutics N.V.
PRQR
$1.47
-$0.06-3.92%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -50.94% | 18.87% | -20.25% | -36.17% | -1.56% |
| Total Other Revenue | -- | -77.52% | -74.56% | 6.79% | 2.46% |
| Total Revenue | -53.24% | 15.92% | -22.13% | -35.13% | -1.38% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -53.24% | 15.92% | -22.13% | -35.13% | -1.38% |
| SG&A Expenses | 29.89% | 8.59% | 1.03% | 68.54% | -9.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.93% | 3.86% | 18.92% | 70.04% | 18.42% |
| Operating Income | -37.61% | 1.45% | -37.68% | -258.77% | -29.84% |
| Income Before Tax | -44.80% | -4.68% | -44.35% | -343.39% | -27.64% |
| Income Tax Expenses | -- | -- | -- | 109.48% | -- |
| Earnings from Continuing Operations | -44.80% | -4.69% | -44.35% | -377.04% | -27.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.80% | -4.69% | -44.35% | -377.04% | -27.58% |
| EBIT | -37.61% | 1.45% | -37.68% | -258.77% | -29.84% |
| EBITDA | -39.35% | 1.72% | -40.59% | -322.44% | -33.09% |
| EPS Basic | -44.79% | 1.20% | -11.92% | -269.58% | 1.18% |
| Normalized Basic EPS | -44.60% | 1.28% | -11.88% | -244.12% | 1.10% |
| EPS Diluted | -41.83% | 1.20% | -11.10% | -283.66% | -3.24% |
| Normalized Diluted EPS | -44.60% | 1.28% | -11.88% | -244.12% | 1.10% |
| Average Basic Shares Outstanding | 0.06% | 5.96% | 28.97% | 28.99% | 29.09% |
| Average Diluted Shares Outstanding | 0.06% | 5.96% | 28.97% | 28.99% | 29.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |